[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Orrego JJ, Barkan AL: Pituitary disorders. Drug treatment options. Drugs; 2000 Jan;59(1):93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary disorders. Drug treatment options.
  • Pituitary tumours can cause symptoms of mass effect and hormonal hypersecretion that can be reversed with surgical resection or debulking of the adenoma, radiotherapy, or medical treatment.
  • Transsphenoidal adenomectomy is the treatment of choice for acromegaly, Cushing's disease, gonadotropin-secreting tumours; and thyrotropin (TSH)-secreting adenomas.
  • Pituitary irradiation and medical therapy are secondary options.
  • Conversely, medical treatment is the primary choice for prolactinomas.
  • Dopamine agonists are very effective in the treatment of prolactin (PRL)-secreting tumours, with rates of control as high as 80 to 90% for microprolactinomas (< 10 mm) and 60 to 75% for macroprolactinomas (> or = 10 mm).
  • Somatostatin analogues have also shown efficacy in patients with acromegaly who have not responded to surgery or in patients with TSH-secreting adenomas who have not improved with surgery and radiotherapy.
  • Although the classic sequence of loss of pituitary secretion is growth hormone (GH), gonadotropins, TSH, and corticotropin (ACTH), the order to begin the replacement therapy of the deficient hormone(s) is cortisol, thyroxine, androgens/estrogens and, if necessary, GH.
  • In general, the hormone replacement therapy is lifelong.
  • [MeSH-major] Adenoma / drug therapy. Hypopituitarism / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):172-7 [8988897.001]
  • [Cites] J Clin Invest. 1993 Aug;92(2):695-701 [8349808.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1285-92 [9345079.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):707-14 [8594431.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):876-83 [9062500.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):174-80 [8008032.001]
  • [Cites] N Engl J Med. 1983 Sep 22;309(12 ):704-9 [6888442.001]
  • [Cites] J Androl. 1994 May-Jun;15(3):212-5 [7928661.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Aug;45(2):171-8 [8881449.001]
  • [Cites] J Clin Endocrinol Metab. 1990 May;70(5):1426-30 [2159485.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):559-64 [7749496.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2646-52 [9709926.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):634-7 [9024267.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):917-24 [2565913.001]
  • [Cites] Eur J Endocrinol. 1996 Nov;135(5):559-67 [8980158.001]
  • [Cites] Clin Obstet Gynecol. 1996 Jun;39(2):506-10 [8734015.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jul;67(1):180-5 [2967850.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):904-9 [7915824.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Endocrinol Jpn. 1992 Aug;39(4):385-95 [1332855.001]
  • [Cites] Lancet. 1976 Aug 21;2(7982):426 [73893.001]
  • [Cites] J Endocrinol Invest. 1990 Dec;13(11):923-9 [2090672.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):216-22 [2115044.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15892-7 [8195244.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1144-51 [3372679.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):518-23 [9024247.001]
  • [Cites] Drugs. 1998 Jul;56(1):49-57 [9664198.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Oct;53(4):737-43 [7287863.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):514-7 [9024246.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Aug;33(2):161-9 [2225475.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Nov;119(3):435-42 [2847474.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3187-91 [9329336.001]
  • [Cites] Horm Res. 1996;46(4-5):155-9 [8950613.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):382-95 [9467546.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):18-22 [8989225.001]
  • [Cites] N Engl J Med. 1985 Sep 12;313(11):656-9 [4022058.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Lancet. 1997 Feb 8;349(9049):413-7 [9033482.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] J Clin Pharmacol. 1976 Nov-Dec;16(11-12):645-51 [993360.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jan;74(1):75-83 [1727832.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):143-69, vii [10207689.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):461-5 [8045964.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3267-72 [7593436.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Endocrinol Invest. 1994 Feb;17(2):135-9 [8006335.001]
  • [Cites] Ann Intern Med. 1998 Sep 15;129(6):472-83 [9735086.001]
  • [Cites] Hum Reprod Update. 1995 Mar;1(2):188-99 [15726772.001]
  • [Cites] Obstet Gynecol. 1989 Mar;73(3 Pt 2):517-20 [2915884.001]
  • [Cites] Ann Med. 1998 Apr;30(2):159-68 [9667794.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):275-9 [9242812.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):786-95; discussion 796-7 [9316039.001]
  • [Cites] Endocr Rev. 1993 Aug;14 (4):443-58 [7693447.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Sep;61(3):580-4 [2410444.001]
  • [Cites] Ann Intern Med. 1992 Nov 1;117(9):711-8 [1416572.001]
  • [Cites] Ann Intern Med. 1990 May 1;112(9):668-73 [1970714.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Dec;23(4):749-72 [7705318.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] N Engl J Med. 1994 Jun 9;330(23):1651-62 [8043090.001]
  • [Cites] Drugs. 1996 Jun;51(6):954-65 [8736617.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Mar;46(3):255-61 [9156031.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Mar;46(3):263-8 [9156032.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1204-10 [1430080.001]
  • [Cites] N Engl J Med. 1996 Oct 17;335(16):1206-12 [8815944.001]
  • [Cites] Fertil Steril. 1993 Mar;59(3):671-3 [8458475.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Apr;60(4):698-705 [3882737.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35 [1355728.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Dec;59(6):1220-3 [6436289.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):379-81 [9467545.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):3-8 [8989221.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6 [9578821.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Aug;35(2):169-78 [1657460.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3567-75 [8530600.001]
  • [Cites] Horm Res. 1997;48 Suppl 5:21-30 [9434041.001]
  • [Cites] N Engl J Med. 1979 Mar 1;300(9):459-64 [215912.001]
  • [Cites] Drugs. 1998 Feb;55(2):253-8; discussion 259 [9506244.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):996-1000 [9100563.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2768-75 [7673422.001]
  • [Cites] Ann Surg. 1994 Apr;219(4):416-25 [8161268.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1363-8 [8496331.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1573-8 [1872661.001]
  • (PMID = 10718101.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  • [Number-of-references] 88
  •  go-up   go-down


2. Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K: Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J; 2007 Feb;54(1):133-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
  • In TSH-secreting pituitary adenomas (TSHoma), octreotide (OCT) therapy reduces tumor size and TSH secretion in some cases but not in others.
  • As OCT acts through various types of somatostatin receptors (SSTRs), the different responses of TSHoma to OCT might be explained by the differences of SSTR expression.
  • We therefore studied the expression of subtype-specific SSTR mRNA transcripts in tumor tissues by RT-PCR.
  • Type 2 (SSTR2) mRNA transcripts were detected in all 8 tumors but those of SSTR3 and SSTR5 were demonstrated only in 5 of them.
  • Serum TSH levels were decreased by OCT administration test in all patients but OCT therapy was effective in two patients out of three.
  • These observations suggest that the temporal decrease of TSH by OCT may be mediated by SSTR2, and that the long term response to OCT therapy may be related with the expression of SSTR5.
  • Therefore, the expression of SSTR5 in TSHoma may be a useful marker for predicting the outcome of the therapy, but further studies with larger numbers of patients are necessary.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / genetics. Biomarkers, Tumor / genetics. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / genetics. Receptors, Somatostatin / genetics. Thyrotropin / secretion
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Prognosis. Protein Isoforms / genetics. Time. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159301.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 5; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


3. Baba T, Endo T, Kitajima Y, Kamiya H, Moriwaka O, Saito T: Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event. Fertil Steril; 2009 Jul;92(1):390.e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event.
  • OBJECTIVE: To report a rare case of spontaneous ovarian hyperstimulation syndrome (OHSS) associated with spontaneous pregnancy and a FSH-secreting pituitary adenoma.
  • In addition, her TSH level was normal, and hCG was appropriate for the date of pregnancy.
  • Subsequently, the patient developed massive thrombophlebitis in her right internal jugular and subclavian veins.
  • No mutations of the FSH receptor, LH receptor, or aromatase genes were detected, but magnetic resonance imaging (MRI) of the head revealed a pituitary adenoma.
  • CONCLUSION(S): A gonadotropin-secreting adenoma caused ovarian hyperstimulation (ovarian enlargement and hyperestrogenemia).
  • [MeSH-major] Adenoma / complications. Ovarian Hyperstimulation Syndrome / complications. Pituitary Neoplasms / complications. Pregnancy Complications / etiology
  • [MeSH-minor] Adult. Anticoagulants / therapeutic use. Dilatation and Curettage. Estrogens / blood. Female. Follicle Stimulating Hormone / secretion. Humans. Paracentesis. Pregnancy. Thrombosis / complications. Thrombosis / drug therapy. Ultrasonography, Prenatal / adverse effects


Advertisement
4. Koch CA, Skarulis MC, Patronas NJ, Sarlis NJ: [TSH-secreting pituitary adenoma: 16 years follow-up]. Med Klin (Munich); 2000 Jan 15;95(1):49-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [TSH-secreting pituitary adenoma: 16 years follow-up].
  • [Transliterated title] TSH-sezernierendes Hypophysenadenom: 16 Jahre Follow-up (TSH-secreting pituitary adenoma).
  • [MeSH-major] Adenoma / secretion. Pituitary Neoplasms / secretion. Thyrotropin / biosynthesis
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / therapeutic use. Follow-Up Studies. Humans. Hypophysectomy. Male. Neoplasm, Residual / drug therapy. Neoplasm, Residual / surgery. Octreotide / therapeutic use. Pituitary Hormones / blood. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10668345.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Pituitary Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Alves C, Alves AC: Primary hypothyroidism in a child simulating a prolactin-secreting adenoma. Childs Nerv Syst; 2008 Dec;24(12):1505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hypothyroidism in a child simulating a prolactin-secreting adenoma.
  • OBJECTS: To report a case of primary hypothyroidism associated to hyperprolactinemia mimicking a prolactin secreting adenoma.
  • Diagnostic evaluation demonstrated free thyroxine (F-T4): 0.22 ng/dL (0.75-1.80) and thyroid-stimulating hormone (TSH): 135 UI/mL (0.3-5.0).
  • Due to the possibility of a pseudoprolactinoma caused by hyperplasia of the TSH and prolactin-producing cells, she was treated for the primary hypothyroidism with levothyroxine.
  • After 2 months, F-T4, TSH, and prolactin returned to normal values.
  • [MeSH-major] Adenoma / diagnosis. Hypothyroidism / diagnosis. Pituitary Neoplasms / diagnosis. Prolactin / secretion
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Hyperprolactinemia / blood. Hyperprolactinemia / drug therapy. Magnetic Resonance Imaging. Thyroxine / administration & dosage. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Reprod Med. 2002 Nov;20(4):365-74 [12536359.001]
  • [Cites] CMAJ. 2003 Sep 16;169(6):575-81 [12975226.001]
  • [Cites] Fertil Steril. 2005 Jul;84(1):181-5 [16009175.001]
  • [Cites] Horm Res. 2005;63(2):61-4 [15668525.001]
  • [Cites] Eur Radiol. 2000;10(3):516-8 [10757007.001]
  • [Cites] Intern Med. 2001 Aug;40(8):751-5 [11518117.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):808-11 [9062487.001]
  • [Cites] Treat Endocrinol. 2003;2(1):23-32 [15871552.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):276-9 [7829625.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):195-7 [9732247.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Sep;30(3):585-610 [11571932.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2004 Jun;48(3):423-6 [15640908.001]
  • [Cites] Australas Radiol. 1999 Feb;43(1):121-3 [10901888.001]
  • [Cites] Pediatr Neurol. 1994 Mar;10(2):166-8 [8024669.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001 Nov-Dec;14(9):1665-9 [11795659.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] Indian Pediatr. 2001 Apr;38(4):432-3 [11313523.001]
  • [Cites] JAMA. 1989 Dec 8;262(22):3175-7 [2810675.001]
  • [Cites] Br J Neurosurg. 1990;4(2):107-12 [2357279.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2005 Jun;49(3):468-72 [16544004.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):185-91 [12580934.001]
  • (PMID = 18690463.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-62-4 / Prolactin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


6. Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S: [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva Endocrinol; 2001 Sep;26(3):181-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs.
  • Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial.
  • Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas.
  • Scintigraphy with octreotide may help to select patients who respond to this form of treatment.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Pentetic Acid / analogs & derivatives. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Acromegaly / drug therapy. Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adult. Aged. Carcinoma / radionuclide imaging. Humans. Indium Radioisotopes / therapeutic use. Insulin-Like Growth Factor I / secretion. Kidney Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Middle Aged. Pheochromocytoma / radionuclide imaging. Predictive Value of Tests. Prolactinoma / drug therapy. Radiopharmaceuticals / therapeutic use. Sensitivity and Specificity. Thymoma / radionuclide imaging. Thymus Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyrotropin / secretion. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753242.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Indium Radioisotopes; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 118992-92-0 / lanreotide; 142694-57-3 / SDZ 215-811; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 7A314HQM0I / Pentetic Acid; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 95
  •  go-up   go-down


7. Marek J: [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?]. Vnitr Lek; 2010 Jul;56(7):690-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
  • To treat pituitary adenomas, three modes of treatment are usually combined: neurosurgery, radiation and pharmacological.
  • Prolactinomas are an exception with predominantly pharmacological management.
  • Patients with acromegaly are usually diagnosed late and thus many neurosurgeries fail to completely remove the adenoma.
  • Any residual tumour tissue is usually irradiated with the Leksell Gamma Knife, and dopamine agonists, somatostatine analogues or growth hormone receptor antagonists are used to normalize the hormonal hypersecretion until the complete effect of the radiation.
  • The same surgical and Gamma Knife procedures are used in patients with the Cushing's disease and TSH-secreting adenomas.
  • Ketoconazole, metyrapone and cabergoline are used until the radiation effect in the Cushing's disease is complete, similarly, somatostatine analogues are used in TSH-secreting adenomas.
  • Nonfunctional adenomas are less responsive to pharmacological treatment.
  • [MeSH-major] Adenoma / therapy. Pituitary Neoplasms / therapy
  • [MeSH-minor] Acromegaly / etiology. Humans. Pituitary ACTH Hypersecretion / etiology. Prolactinoma / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842914.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  •  go-up   go-down


8. Mezosi E, Nemes O: [Treatment of pituitary adenomas]. Orv Hetil; 2009 Sep 27;150(39):1803-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pituitary adenomas].
  • The first-line therapy of prolactinomas are the dopamine agonists, and the aims of the treatment are to normalize the prolactin level, restore fertility in child-bearing age, decrease tumor mass, save or improve the residual pituitary function and inhibit the relapse of the disease.
  • In case of tumors with good therapeutic response, medical therapy can be withdrawn after 3-5 years; hyperprolactinemia will not recur in 2/3 of these patients.
  • Neurosurgery is the primary therapy of GH-, ACTH-, TSH-producing and inactive adenomas.
  • Acromegalic patients with unresectable tumors have a great benefit from somatostatin analog treatment.
  • The growth hormone receptor antagonist pegvisomant is the newest modality for the treatment of acromegaly.
  • The medical therapy of Cushing's disease is still based on the inhibition of steroid production.
  • The rare TSH-producing tumor can respond to both dopamine agonist and somatostatin analog therapy.
  • The application of conventional radiotherapy has decreased; radiotherapy is mainly used in the treatment of invasive, incurable or malignant tumors.
  • Further studies are needed to elucidate the exact role of radiosurgery and fractionated stereotaxic irradiation in the treatment of pituitary tumors.
  • [MeSH-major] Adenoma / therapy. Pituitary Hormones / blood. Pituitary Neoplasms / therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / therapy. Acromegaly / drug therapy. Acromegaly / etiology. Adrenocorticotropic Hormone / blood. Aminoquinolines / therapeutic use. Bromocriptine / therapeutic use. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Dopamine Agonists / therapeutic use. Female. Growth Hormone-Secreting Pituitary Adenoma / therapy. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / blood. Human Growth Hormone / therapeutic use. Humans. Hypophysectomy. Incidental Findings. Male. Pregnancy. Pregnancy Complications, Neoplastic / therapy. Prolactinoma / therapy. Radiosurgery. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758960.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dopamine Agonists; 0 / Pituitary Hormones; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 80Q9QWN15M / quinagolide; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin; 98H1T17066 / pasireotide
  • [Number-of-references] 28
  •  go-up   go-down


9. Oliveira JH, Barbosa ER, Kasamatsu T, Abucham J: Evidence for thyroid hormone as a positive regulator of serum thyrotropin bioactivity. J Clin Endocrinol Metab; 2007 Aug;92(8):3108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The regulation of TSH bioactivity in humans is not completely understood.
  • OBJECTIVE: The aim of the study was to investigate the role of serum thyroid hormones in regulating the bioactivity of TSH.
  • DESIGN: We determined in vitro TSH bioactivity and glycosylation in nine patients (six females and three males, age 41.3 yr) with primary hypothyroidism before and after L-T(4) replacement, in 11 age- and sex-comparable controls (seven females and four males, age 37.6 yr), and in two thyroidectomized patients with TSH-secreting adenomas during and after L-T(4) withdrawal.
  • METHODS: In vitro TSH bioactivity was measured by a sensitive and specific bioassay based on cAMP generation by Chinese hamster ovary cells transfected with human TSH receptor.
  • TSH glycosylation was assessed by concanavalin A lectin and ricin column affinity chromatography.
  • RESULTS: In vitro TSH bioactivity in hypothyroid patients was low as compared with controls (0.48 +/- 0.1 vs. 1.1 +/- 0.2; P = 0.004) and increased during L-T(4) (0.48 +/- 0.1 vs. 0.8 +/- 0.1; P = 0.01).
  • A strong significant correlation (r = +0.80; P = 0.004, Spearman) was observed between the absolute increments of serum TSH bioactivity and T(3) during L-T(4) replacement.
  • The degree of sialylation was elevated in hypothyroid patients before treatment (47 +/- 2.4% vs. 29 +/- 4.3%; P = 0.002) and decreased significantly after L-T(4) (47 +/- 2.4% vs. 33 +/- 4.3%; P = 0.02).
  • The mannose content of serum TSH in hypothyroid patients was similar to controls and did not change during L-T(4).
  • In vitro TSH bioactivity also decreased in patients with TSH-secreting adenomas during L-T(4) withdrawal.
  • CONCLUSION: These data indicate that serum thyroid hormone level is a positive regulator of TSH bioactivity.
  • [MeSH-minor] Adenoma / metabolism. Adult. Animals. CHO Cells. Chromatography, Affinity. Concanavalin A / chemistry. Cricetinae. Cricetulus. Cyclic AMP / biosynthesis. Female. Glycosylation. Hormone Replacement Therapy. Humans. Hypothyroidism / blood. Hypothyroidism / drug therapy. Immunoassay. Male. Mannose / blood. Middle Aged. Neuraminidase / chemistry. Receptors, Thyrotropin / genetics. Receptors, Thyrotropin / metabolism. Ricin / chemistry. Thyroidectomy. Thyroxine / therapeutic use. Transfection

  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. RICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504893.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 0 / Thyroid Hormones; 11028-71-0 / Concanavalin A; 9002-71-5 / Thyrotropin; 9009-86-3 / Ricin; E0399OZS9N / Cyclic AMP; EC 3.2.1.18 / Neuraminidase; PHA4727WTP / Mannose; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


10. Taylor TJ, Donlon SS, Bale AE, Smallridge RC, Francis TB, Christensen RS, Burma KD: Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1. Thyroid; 2000 Nov;10(11):1001-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1.
  • OBJECTIVE: To note that a thyrotropin (TSH)-secreting macroadenoma may be part of the multiple endocrine neoplasia-1 (MEN-1) syndrome and to report the use of octreotide-LAR (OCT-LAR) to treat a TSH-secreting macroadenoma in a patient with MEN-1 with previous surgery for hyperparathyroidism and gastrinoma.
  • METHODS: We present a patient with a TSH-secreting pituitary macroadenoma and report the results of her endocrine, genetic, radiologic, and nuclear medicine testing and her response to treatment with octreotide (OCT), octreotide-LAR, and estrogen.
  • RESULTS: This patient's TSH-induced hyperthyroidism responded to octreotide for 5 months and octreotide-LAR for more than 11 months.
  • (1) The use of octreotide-LAR to treat both a TSH-secreting pituitary tumor and a gastrinoma over 12 months;.
  • [MeSH-major] Adenoma / drug therapy. Hormones / administration & dosage. Multiple Endocrine Neoplasia Type 1 / drug therapy. Octreotide / administration & dosage. Thyroid Neoplasms / drug therapy. Thyrotropin / secretion
  • [MeSH-minor] Estrogens / administration & dosage. Female. Humans. Hypercalcemia / etiology. Hyperthyroidism / drug therapy. Hyperthyroidism / etiology. Hyperthyroidism / radionuclide imaging. Middle Aged

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11128714.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


11. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S: Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J; 2004 Apr;51(2):227-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
  • To investigate the potential pathophysiologic role of human SRIF receptor gene expression in GH-secreting adenomas in acromegalic patients, we studied the relationship between the SRIF receptor gene expression, endogenous SRIF activity and exogenous response to octreotide in 16 acromagalic patients.
  • Hypothalamic somatostatinergic activity (HSA) was assessed by glucose-induced suppression of TRH-stimulated TSH secretion.
  • Pituitary tumor SRIF receptor subtype 2 and 5 (sst2 and sst5) mRNA levels were measured by real-time RT-PCR.
  • These results suggest common transcriptional and/or post-transcriptonal regulatory mechanisms for these SRIF receptor subtypes within GH-secreting pituitary adenomas.
  • The functional observations suggest that the degree (or level) of sst2 and sst5 expression is critical for the ultimate GH response of somatotropinomas to endogenous SRIF tone and exogenous SRIF analogue therapy.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / metabolism. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / metabolism. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Acromegaly / drug therapy. Adult. Female. Gene Expression. Human Growth Hormone / secretion. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15118275.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


12. Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G: Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol; 2007 Apr;156 Suppl 1:S57-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
  • Medical treatment with somatostatin analogues is a cornerstone of GH- and TSH-secreting tumours, while treatment with dopamine agonists is a cornerstone of prolactin-secreting tumours.
  • Dopamine agonists have also demonstrated some efficacy in patients with GH- and TSH-secreting adenomas.
  • Neither ACTH-secreting nor clinically non-functioning tumours have a well-established medical treatment.
  • Combination treatment with both somatostatin analogues and dopamine agonists has been poorly investigated.
  • Some studies conducted in small series have documented an additive effect of both drugs in patients with GH-secreting adenomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Endocrinol. 2007 Oct;157(4):543
  • (PMID = 17413190.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Dopamine; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  • [Number-of-references] 59
  •  go-up   go-down






Advertisement